Valuation: Corvus Pharmaceuticals, Inc.

Market Cap 886M 791M 731M 662M 1.24B 84.09B 1.26B 8.79B 3.48B 44.06B 3.32B 3.25B 139B P/E 2026 *
-13.7x
P/E 2027 * -11x
Enterprise Value 701M 626M 578M 524M 980M 66.54B 997M 6.96B 2.76B 34.86B 2.63B 2.57B 110B EV / Sales 2026 *
-
EV / Sales 2027 * 137x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
09-30 Corvus Pharmaceuticals, Inc. Begins Enrollment In Phase 1b Clinical Trial Of Soquelitinib For Treatment Of Patients With Hidradenitis Suppurativa CI
08-27 Corvus Pharmaceuticals Publishes Final Phase 1 Data from Soquelitinib Phase 1/1B T Cell Lymphoma Trial CI
08-06 Corvus Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06 Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-22 Corvus Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from Board of Directors, Effective July 22, 2026 CI
06-09 Angel Pharmatech Ltd. announced that it has received $13.5 million in funding from Corvus Pharmaceuticals, Inc. and other investors CI
06-08 Angel Pharmaceuticals announced that it has received CNY 100 million in funding from Corvus Pharmaceuticals, Inc., Zhejiang Yisheng Yihua Investment Management Co., Ltd., Jiangsu Ruihua Venture Capital Management Co., Ltd. and other investors CI
06-08 Corvus Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 11:20 AM
05-14 Corvus Pharmaceuticals, Inc. - Shareholder/Analyst Call
05-14 Corvus Pharmaceuticals, Inc. Presents Final Data From Soquelitinib Phase 1 Atopic Dermatitis Clinical Trial CI
05-07 Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-23 Corvus Pharmaceuticals, Inc. Appoints Andrew C. Chan to Board of Directors CI
04-17 Goldman Sachs Initiates Corvus Pharmaceuticals at Buy With $40 Price Target MT
1 day-1.13%
1 week+10.61%
Current month-8.59%
1 month-16.03%
3 months-23.03%
6 months-34.27%
Current year+36.75%
1 week 9.5
Extreme 9.5
10.68
1 month 9.21
Extreme 9.21
12.42
Current year 6.39
Extreme 6.39
26.95
1 year 6.39
Extreme 6.39
26.95
3 years 1.05
Extreme 1.05
26.95
5 years 0.61
Extreme 0.607
26.95
10 years 0.61
Extreme 0.607
26.95
Manager TitleAgeSince
Chief Executive Officer 75 2014-01-31
Director of Finance/CFO 71 2014-10-31
Chief Operating Officer - 2020-12-31
Director TitleAgeSince
Director/Board Member 67 2014-10-31
Chairman 75 2014-01-26
Director/Board Member 69 2019-01-27
Date Insider Type Main position Quantity % Market Cap. Importance
5/18/26 Buy

Chief Executive Officer

6,932 0.0082%
4/23/26 Free

Director

30,000 0.0357%
1/28/26 Exercice

Founder

420,000 0.5624%
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%+10.61%+47.07%+807.76% 886M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.14%+3.23%+49.26%+222.57% 38.4B
Weighted average by Cap. +0.39%+2.75%+47.57%+160.07%

Financials

2026 *2027 *
Net sales - 4.55M 4.06M 3.75M 3.4M 6.36M 432M 6.46M 45.13M 17.87M 226M 17.06M 16.7M 713M
Net income -72.74M -64.95M -60.01M -54.38M -102M -6.9B -103M -722M -286M -3.62B -273M -267M -11.41B -92.65M -82.74M -76.43M -69.27M -130M -8.8B -132M -920M -364M -4.61B -348M -340M -14.53B
Net Debt -185M -165M -152M -138M -258M -17.54B -263M -1.83B -726M -9.19B -694M -679M -28.98B -265M -237M -219M -198M -370M -25.14B -377M -2.63B -1.04B -13.17B -994M -973M -41.53B
Projected Income Statement - Annual - Corvus Pharmaceuticals, Inc.
Logo Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Employees
37
Date Price Change Volume
26-10-23 US$10.53 -1.13% 933,772
26-10-22 US$10.65 +5.97% 1,080,556
26-10-21 US$10.05 -1.76% 868,812
26-10-20 US$10.23 +6.01% 1,066,930
26-10-19 US$9.650 +1.37% 820,335
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Corvus Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.53USD
Average target price
33.14USD
Spread / Average Target
+214.75%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Corvus Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. CRVS Stock